David Drewry

Research Associate Professor (UNC) - Principal Investigator (SGC)

University of North Carolina at Chapel Hill

David Drewry is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy. Drewry enjoys running, reading and relaxing with his family at local restaurants, the movie theater or in the kitchen playing board games.

2015

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromdomain Containing Protein 9 Inhibition
Theodoulou, N.H.; Bamborough, P.; Bannister, A.J.; Becher, I.; Bit, R.A.; Che, K.H.; Chung, C-W.; Dittmann, A.; Drewes, G.; Drewry, D.H.; Gordon, L.; Grandi, P.; Leveridge, M.; Lindon, M.; Michon, A-M.; Molnar, J.; Robson, S.C.; Tomkinson, N.C.O.; Kouzarides, T.; Prinjha, R.K.; Humphreys, P.G.
J. Med. Chem.. 2015 . doi:10.1021/acs.jmedchem.5b00256
PMID:25856009

New compound sets identified from high throughput screening against three kinetoplastid parasites: an open resource
ena, I.; Pilar Manzano, M.; Cantizani, J.; Kessler, A.; Alonso-Padilla, J.; Bardera, A.I.; Alvarez, E.; Colmenarejo, G.; Cotillo, I.; Roquero, I.; de Dios-Anton, F.; Barroso, V.; Rodriquez, A.; Gray, D.W.; Navarro, M.; Kumar, V.; Sherstnev, A.; Drewry, D.H.; Brown, J.R.; Fiandor, J.M.; Martin, Julio J.
Sci. Rep.. 2015 5:8771. doi:10.1038/srep08771
PMID:25740547

2016

Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
Chen, P; Chaikuad, A; Bamborough, P; Bantscheff, M; Bountra, C; Chung, CW; Fedorov, O; Grandi, P; Jung, D; Lesniak, R; Lindon, M; Müller, S; Philpott, M; Prinjha, R; Rogers, C; Selenski, C; Tallant, C; Werner, T; Willson, TM; Knapp, S; Drewry, DH;
Journal of Medicinal Chemistry. 2016 59:1410-1424. doi:
PMID:25799074

2014

Seeding collaborations to advance kinase science with the GSK Published Kinase Inhibitor Set (PKIS)
Drewry DH, Willson TM, Zuercher WJ.
Curr Top Med Chem. 2014 14(3):340-2. doi:
PMID:24283969

2013

Profile of the GSK published kinase inhibitor set across ATP-dependent and –independent luciferases: implications for reporter-gene assays
Dranchak, P.; MacArthur, R.; Guha, R.; Zuercher, W.J.; Drewry, D.H.; Auld, D.S.; Inglese, J.
PLoS One. 2013 8(3):e57888. doi:10.1371/journal.pone.0057888
PMID:23505445

Plasmodium kinases as targets for new-generation antimalarials
Lucet, I.S.; Tobin, A.; Drewry, D.; Wilks, A.F.; Doerig, C.
Future Med. Chem.. 2013 2295-310. doi:10.4155/fmc.12.183
PMID:23234552

2010

A Rapid Three-Component MgI2 Mediated Synthesis of 3,3-Pyrrolidinyl Spirooxindoles
Helan, V.; Mills, A.; Drewry, D.; Grant, D.
J Org Chem.. 2010 6693-5. doi:10.1021/jo101077g
PMID:20804180

Enhancements of screening collections to address areas of unmet medical need: an industry perspective
Drewry, D.H.; Macarron, R.
Curr. Opinion in Chem Biol.. 2010 289-298. doi:10.1016/j.cbpa.2010.03.024
PMID:20413343

Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
Adams, N.D.; Adams, J.L.; Burgess, J.L.; Chaudhari, A.M.; Copeland, R.A.; Donatelli, C.A.; Drewry, D.H.; Fisher, K.E.; Hamajima, T.; Hardwicke, MA.; Huffman, W.F.; Koretke-Brown, K.K.; Lai, Z.V.; McDonald, O.B.; Nakamura, H,; Newlander, K.A.; Oleykowski, C.A.; Parrish, C.A.; Patrick, D.R.; Plant, R.; Sarpong, M.A.; Sasake, K.; Schmidt, S.J.; Silva, D.J.; Sutton, D.; Tang, J.; Thompson, C.S.; Tummino. P.J.; Wang, J.C.; Xiang, H.; Yang, J.; Dhanak, D.
J. Med. Chem.. 2010 3973-4001. doi:10.1021/jm901870q
PMID:20420387

2009

Discovery of thiophene inhibitors of polo-like kinase
Emmitte, K.A.: Andrews, C.W.; Badiang, J.G.; Davis-Ward, R.G.; Dickson, H.D.; Drewry, D.H.; Emerson, H.K.; Epperly, A.H.; Hassler, D.F.; Knick, V.B.; Kuntz, K.W.; Lansing, T.J.; Linn, J.A.; Mook, R.A. Jr.; Nailor, K.E.; Salovich, J.M.; Spehar, G.M.; Cheung, M.
Bioorg. Med. Chem. Lett.. 2009 1018-1021. doi:10.1016/j.bmcl.2008.11.041
PMID:19097784

2008

Assessment of Chemical Coverage of Kinome Space and its Implications for Kinase Drug Discovery
Bamborough, P.; Drewry, D.; Harper, G.; Smith, G.K.; Schneider, K.
J. Med. Chem.. 2008 7898-7914. doi:10.1021/jm8011036
PMID:19035792

Kinase-Targeted Library Design through the Application of the PharmPrint Methodology
Deanda, F.; Stewart, E.L.; Reno, M.J.; Drewry, D.H.
J. Chem Inf. and Model.. 2008 2395-2403. doi:10.1021/ci800276t
PMID:19053525

glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03